Lisanti Capital Growth LLC Purchases 27,180 Shares of GeneDx Holdings Corp. $WGS

Lisanti Capital Growth LLC increased its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 92.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,615 shares of the company’s stock after purchasing an additional 27,180 shares during the period. GeneDx accounts for 1.4% of Lisanti Capital Growth LLC’s portfolio, making the stock its 21st largest holding. Lisanti Capital Growth LLC owned 0.20% of GeneDx worth $5,226,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of WGS. Campbell & CO Investment Adviser LLC purchased a new stake in GeneDx in the 2nd quarter worth $204,000. Penserra Capital Management LLC lifted its position in shares of GeneDx by 29.2% in the second quarter. Penserra Capital Management LLC now owns 26,156 shares of the company’s stock valued at $2,414,000 after acquiring an additional 5,915 shares in the last quarter. EFG Asset Management North America Corp. boosted its stake in shares of GeneDx by 164.5% in the second quarter. EFG Asset Management North America Corp. now owns 29,127 shares of the company’s stock worth $2,688,000 after acquiring an additional 18,114 shares during the period. Bryce Point Capital LLC purchased a new stake in shares of GeneDx during the second quarter worth about $579,000. Finally, Corton Capital Inc. bought a new stake in GeneDx during the 2nd quarter valued at approximately $339,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Trading Up 0.7%

Shares of WGS opened at $139.73 on Friday. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $146.00. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The company’s fifty day simple moving average is $125.41 and its 200-day simple moving average is $100.49. The company has a market cap of $4.01 billion, a P/E ratio of 1,552.56 and a beta of 2.01.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. The company had revenue of $116.74 million for the quarter, compared to analyst estimates of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. GeneDx has set its FY 2025 guidance at EPS. As a group, analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

WGS has been the topic of several research analyst reports. BTIG Research boosted their target price on shares of GeneDx from $140.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Guggenheim reaffirmed a “buy” rating and issued a $170.00 price objective (up previously from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Wells Fargo & Company upped their price objective on GeneDx from $95.00 to $140.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. Piper Sandler raised their target price on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus price target of $129.22.

Insiders Place Their Bets

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47. Following the transaction, the chief executive officer owned 14,578 shares of the company’s stock, valued at $1,770,789.66. This represents a 41.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Casdin Capital, Llc sold 500,000 shares of GeneDx stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $120.90, for a total value of $60,450,000.00. Following the sale, the director owned 3,007,164 shares of the company’s stock, valued at approximately $363,566,127.60. This trade represents a 14.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 556,375 shares of company stock worth $67,569,247 in the last 90 days. 29.60% of the stock is owned by insiders.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.